Loren Data's SAM Daily™

fbodaily.com
Home Today's SAM Search Archives Numbered Notes CBD Archives Subscribe
SAMDAILY.US - ISSUE OF AUGUST 21, 2025 SAM #8669
SPECIAL NOTICE

65 -- Intent to Sole Source PYLARIFY (piflufolastat F 18)

Notice Date
8/19/2025 8:40:48 AM
 
Notice Type
Special Notice
 
NAICS
325412 — Pharmaceutical Preparation Manufacturing
 
Contracting Office
252-NETWORK CONTRACT OFFICE 12 (36C252) MILWAUKEE WI 53214 USA
 
ZIP Code
53214
 
Solicitation Number
36C25225Q0655
 
Response Due
8/26/2025 2:00:00 PM
 
Archive Date
08/31/2025
 
Point of Contact
Stacy Massey, Contracting Office, Phone: 4148448400
 
E-Mail Address
Stacy.Massey@va.gov
(Stacy.Massey@va.gov)
 
Awardee
null
 
Description
The Department of Veterans Affairs, VHA Regional Procurement Office Central, Great Lakes Acquisition Center, Network Contracting Office 12, located at 115 S. 84th Street, Suite 101, Milwaukee, WI 53214-1476 intends to award a sole source, firm-fixed-price delivery order to Progenics Pharmaceuticals, Inc. 331 Treble Cove Road, N. Billerica, MA 01862, for the purchase of Pylarify Injection (Piflufolastat F 18). The associated North America Classification Systems (NAICS) Code is 325412, Pharmaceutical Preparation Manufacturing. The Edward J. Hines, Jr. VA Medical Center, 5000 South 5th Avenue, Hines, IL, 60141-3030, has a requirement for the purchase of Pylarify Injection (Piflufolastat F 18). Pylarify (piflufolastate F18) is highly specialized radiopharmaceutical. Pylarify is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy and or with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. Pylarify combines the accuracy of PET imaging, the precision of PSMA targeting, and the clarity of F18 radioisotope. Per the FDA website https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Pylarify is manufactured for and a trademark of Progenics Pharmaceuticals, Inc. This notice satisfies the requirement at FAR 5.201(b)(1), to publicize the proposed contract action. This notice of intent is not a request for competitive proposals. No solicitation documents are available at this time. Interested parties may give written notice to Stacy.Massey@va.gov by 5:00pm e.s.t. on 08/26/2025. Supporting evidence must be furnished in sufficient detail to demonstrate the ability to meet the subject requirement. This information shall be provided at no cost or obligation to the Government. Responses will be considered by the Government; however, a determination by the Government not to compete the proposed acquisition based upon responses of this notice is solely within the discretion of the Government. Inquiries shall be emailed to Stacy.Massey@va.gov. No telephone requests will be accepted. Any response to this notice must show clear and convincing evidence that competition would be advantageous to the Government in future procurements.
 
Web Link
SAM.gov Permalink
(https://sam.gov/opp/b145ea56d33c47879a4cd9b33319d3ff/view)
 
Record
SN07556499-F 20250821/250819230045 (samdaily.us)
 
Source
SAM.gov Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's SAM Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  Jenny in Wanderland!  © 1994-2024, Loren Data Corp.